Brief: Pharmaust Files Positive Clinical Data With FDA To Support Orphan Drug Designation Request
14/03/2024 01:27
March 14 (Reuters) - Pharmaust Ltd PAA.AX :
* FILES POSITIVE CLINICAL DATA WITH FDA TO SUPPORT ORPHAN
DRUG
DESIGNATION REQUEST
Further company coverage: PAA.AX
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO